Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Hydrocortisone is a short-acting synthetic corticosteroid often utilized in the acute management of asthma exacerbations when oral administration is not feasible or clinical status is severe. It exerts potent anti-inflammatory effects through glucocorticoid receptor binding.
## Primary Indications
* Management of acute, severe asthma exacerbations unresponsive to initial intensive bronchodilator therapy.
* Patients unable to tolerate oral corticosteroids (e.g., severe vomiting, intubation/mechanical ventilation).
## Adult Dosing
* **Initial Dose:** 100 mg IV every 6–8 hours.
* **Maximum Dose:** No strict standardized maximum in acute asthma; dosing is typically titrated based on clinical response and transition to oral therapy.
## Pediatric Dosing
* **Standard Dose:** 2–4 mg/kg/dose IV every 6 hours.
* **Maximum:** Not to exceed 100 mg per dose unless otherwise specified by institutional protocol.
## Dose Adjustments
* **Renal/Hepatic:** No specific dose adjustments are typically required for acute, short-term administration.
* **Transition:** Tapering is generally unnecessary for short courses (<5–7 days). Transition to oral prednisone/prednisolone as soon as the patient can tolerate oral intake.
## Contraindications
* Known hypersensitivity to hydrocortisone or components of the formulation.
* Systemic fungal infections.
* Administration of live or live-attenuated vaccines during high-dose therapy.
## Adverse Effects
* **Common:** Hyperglycemia (especially in diabetic patients), hypertension, fluid retention, and hypokalemia.
* **Psychiatric:** Agitation, insomnia, or psychosis.
* **Serious:** Increased risk of secondary infection, gastrointestinal ulceration/bleeding, and adrenal suppression (with prolonged use).
## Key Drug Interactions
* **Diuretics:** Increased risk of hypokalemia.
* **Antidiabetic Agents:** Reduced efficacy of insulin or oral hypoglycemics; close monitoring of blood glucose is mandatory.
* **NSAIDs:** Increased risk of gastrointestinal ulceration.
* **CYP3A4 Inducers/Inhibitors:** May alter serum concentrations (potential for treatment failure or toxicity).
## Monitoring
* **Clinical:** Respiratory rate, oxygen saturation, work of breathing, and peak flow (if applicable).
* **Laboratory/Vitals:** Blood glucose (especially in known diabetics), blood pressure, and electrolytes (potassium).
## Clinical Pearls
* **Onset:** Systemic corticosteroids require 4–6 hours to show clinical improvement in airway obstruction.
* **Guidelines:** Oral corticosteroids are generally considered as effective as IV formulations in the ED setting if the patient can swallow. Reserve IV for severe illness or vomiting.
* **Protocol Dependency:** Always verify the preferred corticosteroid and dosing schedule with local hospital protocols or institutional acute asthma pathways.
***
**Educational Disclaimer:** This information is for educational purposes only. Dosing, indications, and safety profiles may change based on new clinical evidence or institution-specific protocols. Always consult the most current prescribing information, institutional guidelines, and clinical pharmacist oversight before medication administration.
